New Review Finds Ketamine May Ease Depression Within Hours and Reduce Suicidal Ideation
A new JAMA Psychiatry review adds weight to what many ketamine clinicians have seen in practice: intravenous ketamine can reduce depressive symptoms and suicidal thinking quickly, sometimes within hours. But the research also sharpens a harder clinical question. Once a patient begins to feel better, how do providers help that relief last?
New:Â Get Pre-Screened for a Psychedelic Clinical Trial
| Key Takeaway | What It Means |
|---|---|
| Ketamine worked quickly | A review of 26 randomized clinical trials found rapid reductions in depressive symptoms and suicidal thinking. |
| Benefits appeared within hours | Depressive symptoms improved as early as four hours after a single infusion. |
| Suicidal thinking also fell | Suicidal symptoms improved at 24 hours and, in some data, at one month. |
| Safety findings were reassuring | Serious adverse events were not tied to the intervention, while other effects were generally temporary. |
| Durability remains the challenge | Researchers still need better data on how long benefits last and how best to maintain them. |
| Buprenorphine may be part of the next step | A small new trial found that low dose buprenorphine helped sustain reductions in suicidal thinking after ketamine. |
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
A Larger Look at Ketamine and Depression
The JAMA Psychiatry analysis reviewed 26 randomized clinical trials involving 1,166 patients with a major depressive episode. Some had unipolar depression. Others had bipolar depression or treatment resistant symptoms.
The central finding was clear. Patients who received intravenous ketamine had faster improvement than those in control groups.
For depressive symptoms, improvement appeared at four hours, 24 hours, three days, and one week after a single infusion. Repeated infusions also showed benefit by the end of treatment.
For suicidal symptoms, the review found significant reductions at 24 hours after one infusion. Repeated infusions showed similar reductions at the end of treatment.
Why Speed Matters
Most antidepressants take weeks to work. That delay can leave patients and clinicians in a dangerous gap, especially when suicidal thoughts are present.
Ketamine changes that timeline. It does not replace careful psychiatric care, safety planning, therapy, or follow up. But it may create a window when symptoms ease enough for patients to engage more fully in treatment.
For HealingMaps readers, that distinction matters. Ketamine is not simply another depression treatment. It is often used when standard options have not worked, or when symptoms need faster attention.
The Next Question Is Maintenance
The JAMA review also notes an important limit. Longer term outcomes are still not well established.
That is where a new American Journal of Psychiatry study becomes especially interesting. In that trial, 50 adults with major depression and clinically significant suicidal ideation received one intravenous ketamine infusion. Two days later, they were assigned to low dose buprenorphine or placebo for four weeks.
At week four, suicidal ideation fell 76 percent in the ketamine and buprenorphine group. It fell 43 percent in the ketamine and placebo group.
Depression scores improved in both groups. The difference between groups was not statistically significant for depression. No serious treatment related adverse events occurred.
What Patients Should Take From This
These findings do not mean buprenorphine will become a standard add on for every ketamine patient. The study was small. It excluded people with substance use disorders. Researchers still need to study dosing, tapering, follow up, and safety over time.
But together, the studies point in the same direction. Ketamine may offer rapid relief for some people with severe depression and suicidal thinking. The next phase of research may focus less on whether ketamine can work quickly, and more on how clinicians can extend that benefit safely.
